Status:
RECRUITING
PRostate Olaparib Real World Evidence Study
Lead Sponsor:
AstraZeneca
Conditions:
Metastatic Castration-resistant Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
This French non-interventional prospective multicenter cohort study is conducted to study the added value of olaparib in the treatment of patients with mCRPC in the real world setting in terms of trea...
Eligibility Criteria
Inclusion
- Adult male patients (≥ 18 years old)
- With metastatic castration-resistant prostate cancer - Who have initiated olaparib within the last two months of study entry, or for whom the decision to be treated with olaparib has been made by their physician
- Who have been informed and are not opposed to this data collection
Exclusion
- Patients opposed to the collection of their data
- Patients participating in a clinical trial with an investigational prostate cancer targeted drug within 30 days prior to Olaparib initiation
Key Trial Info
Start Date :
October 11 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 13 2028
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06031805
Start Date
October 11 2023
End Date
October 13 2028
Last Update
October 28 2025
Active Locations (65)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Amiens, France
2
Research Site
Angers, France
3
Research Site
Antony, France
4
Research Site
Argenteuil, France